Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Categorynews

Transactions under Novonesis’ share buyback program

March 25, 2025 Off By GlobeNewswire

Please read the announcement in PDF
Attachment

2025_13_Share_buyback_program

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)

Related

Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting
Better Choice Announces SRx Health’s Participation at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 5th and 6th

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector

December 18, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine
Go to mobile version